Hamlet BioPharma Releases Q3 Report and Secures New Patents
Hamlet BioPharma has released its interim report for the third quarter of 2026, covering January through March. The company also announced the securing of new patents and allowances.
Lund-based Hamlet BioPharma has published its interim report for the third quarter of 2026, which covers the period from January to March.
In parallel with the financial reporting, the company recently announced an expansion of its patent portfolio. Hamlet BioPharma has secured new patents and allowances, strengthening its position in innovation and technology development for the treatment of cancer and infections.
The company is focused on developing a portfolio of drug candidates for cancer and infections. These new patents support the company's strategic objective to enhance its project pipeline.
Further details regarding the company's financial performance and ongoing development projects are available on its website, with additional information expected at upcoming investor meetings.